Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas

John M. Timmerman, MD, Kristopher K Steward, PhD, Reiko E Yamada, Patricia A Young, MD, Dena M. Minning, MD PhD, Raj K Sachdev, PhD, Michael J Gresser, PhD, Sanjay D Khare, PhD, Sherie L Morrison, PhD

Blood (2015) 126 (23): 2762.

https://doi.org/10.1182/blood.V126.23.2762.2762

Published: 2015

Journal Articles

Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo

Reiko E Yamada, Kristopher K Steward, Gataree Ngarmchamnanrith, Sanjay Khare, Raj Sachdev, Iqbal Grewal, Sherie Morrison, John M Timmerman

Blood (2011) 118 (21): 2724.

https://doi.org/10.1182/blood.V118.21.2724.2724

Published: 2011

Journal Articles

Direct Growth Inhibition of Both Mouse and Human B Cell Lymphomas by CpG Oligodeoxynucleotides

Reiko E Yamada, David J Betting, M.S., Michael Ahdoot, Kristopher K Steward, Ph.D., John M Timmerman, M.D.

Blood (2010) 116 (21): 2854.

https://doi.org/10.1182/blood.V116.21.2854.2854

Published: 2010

Journal Articles

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma

Caiyun Xuan, Kristopher K. Steward, John M. Timmerman, Sherie L. Morrison

Blood (2010) 115 (14): 2864–2871.

https://doi.org/10.1182/blood-2009-10-250555

Published: 2010

Journal Articles

In Vivo Eradication of a Rituximab-Resistant Human CD20 + B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement.

David J Betting, Kamran Kafi, Reiko E Yamada, Kristopher K Steward, Tove Olafsen, PhD, Anna M Wu, PhD, Nico van Rooijen, John M Timmerman, MD

Blood (2009) 114 (22): 723.

https://doi.org/10.1182/blood.V114.22.723.723

Published: 2009

Journal Articles

Spectrum of Expression and Biological Activity of Programmed Death Ligand 1 (PD-L1) in Non-Hodgkin’s Lymphomas

David J Andorsky, MD, Reiko Yamada, Kristopher K Steward, BS, Sven De Vos, MD, PhD, Jonathan Said, John M Timmerman, MD

Blood (2008) 112 (11): 4140.

https://doi.org/10.1182/blood.V112.11.4140.4140

Published: 2008

Journal Articles

Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo

Suzanne N. Franki, Kristopher K. Steward, David J. Betting, Kamran Kafi, Reiko E. Yamada, John M. Timmerman

Blood (2008) 111 (3): 1504–1511.

https://doi.org/10.1182/blood-2007-03-080507

Published: 2008

Includes: Supplemental data

NARROW

Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas

Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo

Direct Growth Inhibition of Both Mouse and Human B Cell Lymphomas by CpG Oligodeoxynucleotides

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma

In Vivo Eradication of a Rituximab-Resistant Human CD20 + B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement.

Spectrum of Expression and Biological Activity of Programmed Death Ligand 1 (PD-L1) in Non-Hodgkin’s Lymphomas

Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo

Email alerts

ASH Publications

American Society of Hematology

Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas

Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo

Direct Growth Inhibition of Both Mouse and Human B Cell Lymphomas by CpG Oligodeoxynucleotides

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma

In Vivo Eradication of a Rituximab-Resistant Human CD20 + B Cell Lymphoma by Rituximab-CpG Oligodeoxynucleotide Conjugate Is Mediated by Natural Killer Cells and Complement.

Spectrum of Expression and Biological Activity of Programmed Death Ligand 1 (PD-L1) in Non-Hodgkin’s Lymphomas

Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only